Tuesday, September 29, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 3, 2026

AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth

View original at globenewswire.com
AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "AI in Genomics Market, till 2040: Distribution by Type of Component, Type of Technology, Type of Functionality…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The rapid increase in genomic data generated by next-generation sequencing technologies has created a strong demand for AI-based tools capable of managing and analyzing complex datasets

    80% confidence
  • The AI in genomics market will grow at a CAGR of 43.75% during the forecast period till 2040

    80% confidence
  • Machine learning algorithms are enabling faster identification of genetic patterns, disease prediction, and drug target discovery, thereby significantly reducing both cost and time in research and development

    80% confidence
  • The global AI in genomics market size is estimated to grow from USD 1.97 billion in 2026 to USD 317.4 billion by 2040

    80% confidence
  • Drug development has traditionally been a lengthy and costly process, often taking several years and substantial investment, but AI-driven tools now enable rapid analysis of vast biomedical datasets

    80% confidence
  • The AI in genomics market faces several critical challenges including data quality and standardization issues, data privacy and compliance concerns, high computational costs, limited availability of skilled AI professionals, and lack of model interpretability

    80% confidence
  • AI algorithms can predict molecular interactions, optimize lead compounds, and identify potential drug candidates with higher precision

    80% confidence
  • The integration of AI into drug discovery and genomics is reshaping the healthcare landscape, expediting innovation, and advancing the global shift toward precision medicine

    80% confidence
  • The market for AI in genomics is expected to grow significantly due to the massive increase in genomic data from next-generation sequencing technologies, which outpaces traditional analysis methods and requires AI's pattern recognition capabilities

    80% confidence
  • Artificial intelligence is transforming the field of genomics by processing huge datasets from DNA sequencing to reveal insights that conventional techniques overlook

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,314 source documents archived
Query this data → isubstrate.com